Meta Information
ID:nmn-liposomal
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/condition/active-cancer
Target name:
Active Cancer
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
NAD+ is essential for cellular energy and proliferation, and rapidly dividing cancer cells have high NAD+ demands. Supplementing with NMN could theoretically fuel cancer growth.
Actionable advice:
NMN should be avoided completely with an active cancer diagnosis, unless directed by an oncologist.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Precautionary inference: NAD+ fuels cell energy, proliferation and DNA repair, so boosting NAD+ with NMN is a theoretical concern in active malignancy (it could in principle support tumour metabolism). Preclinical data are mixed and there are no human cancer-outcome data; precaution is reasonable but unproven.
Label source:
Class inference
Action type:
avoid
Target id:
/class/chemotherapy-radiation
Target name:
Cytotoxic Cancer Therapies (Chemotherapy & Radiation)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
NMN boosts NAD+, which supports cellular repair mechanisms. This could potentially counteract the intended DNA-damaging and cell-killing effects of chemotherapy and radiation.
Actionable advice:
NMN should not be taken during active cancer treatment with chemotherapy or radiation.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
In the placebo group, one patient with FIGO Stage IB cancer received radiation therapy and the patient with FIGO Stage IVB cancer received chemotherapy and hormonal therapy.
Label source:
Action type:
avoid
Target id:
/class/parp-inhibitors
Target name:
PARP Inhibitor Medications
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
PARP inhibitors are cancer drugs that work by blocking a DNA repair enzyme that consumes NAD+. Increasing NAD+ levels with NMN could potentially counteract the therapeutic effect of these drugs.
Actionable advice:
NMN should not be taken during treatment with a PARP inhibitor (e.g., olaparib, rucaparib).
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: PARP enzymes consume NAD+ to repair DNA; raising NAD+ with NMN could in theory support the very repair that PARP inhibitors aim to block in cancer cells. Theoretical pharmacodynamic opposition, not demonstrated clinically.
Label source:
Class inference
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The effects of NMN supplementation on fetal development are unknown. Due to a lack of safety data, it is contraindicated during pregnancy.
Actionable advice:
NMN should be avoided completely during pregnancy.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
It is not known if NMN or its metabolites are excreted in breast milk or what their effects on a nursing infant might be.
Actionable advice:
NMN should be avoided completely while breastfeeding.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/intervention/betaine
Target name:
Betaine (TMG)
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
NMN increases NAD+ levels, and the subsequent breakdown of nicotinamide consumes methyl groups. TMG provides these methyl groups, preventing their depletion and supporting the NAD+ cycle.
Actionable advice:
TMG is best taken concurrently with the NMN dose to support methylation, typically at a 1:1 or 1:2 ratio (NMN:TMG).
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: clearing the nicotinamide generated by NAD+ turnover uses methylation (via NNMT), which consumes methyl groups and can raise homocysteine; betaine is a methyl donor that could offset this. Coherent biochemistry; the NMN+betaine combination is not formally studied.
Label source:
Class inference
Action type:
informational_none
Target id:
/circadian/wake
Target name:
Waking Up
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
null
Hours after target:
2
Description:
NAD+ levels naturally peak during the day to support energy and metabolism. Taking NMN in the morning aligns with this endogenous rhythm, potentially enhancing its effects.
Actionable advice:
An NMN dose is best taken in the morning, ideally within two hours of waking.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: NAD+ and its biosynthesis follow a circadian rhythm that peaks during the active phase, so morning dosing aligns NMN with the natural NAD+ cycle. Physiology-based timing advice.
Label source:
Class inference
Action type:
informational_none
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
moderate
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
6
Hours after target:
null
Description:
NMN boosts NAD+ and cellular energy production, which may have a stimulating effect for some individuals, potentially interfering with sleep onset or quality.
Actionable advice:
NMN is best taken more than 6 hours before intended bedtime.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: by raising NAD+ and cellular energy production, NMN may be mildly activating; taking it late could theoretically affect sleep. Practical timing caution, not demonstrated.
Label source:
Class inference
Action type:
separate
Target id:
/biomarker/homocysteine
Target name:
Homocysteine
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The metabolic breakdown of nicotinamide (from the NAD+ cycle) consumes methyl groups, which can lead to an increase in homocysteine levels if methyl donor intake is inadequate.
Actionable advice:
Homocysteine levels should be monitored periodically, especially with high-dose NMN, and adequate intake of methyl donors is important.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: NAD+ turnover -> nicotinamide -> NNMT methylation consumes S-adenosylmethionine and can raise homocysteine; periodic homocysteine monitoring during chronic NMN use is a reasonable precaution. Biochemically grounded, not confirmed in trials.
Label source:
Class inference
Action type:
monitor
Target id:
/intervention/resveratrol
Target name:
Resveratrol
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
NMN provides the fuel (NAD+) for sirtuin enzymes, while resveratrol acts as an activator for these enzymes, potentially creating a synergistic effect on cellular health.
Actionable advice:
Consider taking resveratrol at the same time as NMN to potentially enhance sirtuin activity.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Recent studies have provided a proof of concept for the idea that nicotinamide mononucleotide (NMN), the NAMPT reaction product, can be used as a nutriceutical to activate SIRT1 activity.
Label source:
PubMed: Pharmacological research (2010)
Source url:
Exact phrase from label:
By analyzing the prevention of NAD+ degradation through the inhibition of CD38 or supporting protective downstream agents of SIRT1, we provide a potential framework of the CD38/NAD+/SIRT1 axis through which geroprotectors may enhance the efficacy of NAD+ precursor supplementation and reduce the risk of age-related diseases, thereby potentiating healthspan in humans.
Label source:
PubMed: Nutrients (2023)
Source url:
Exact phrase from label:
Compared with NMN alone, NMN combined with resveratrol could increase the levels of NAD+ in the heart and muscle by about 1.6 times and 1.7 times, respectively, whereas NMN coupled with ginsenoside Rh2&Rg3 could effectively improve the level of NAD+ in lung tissue for approximately 2.0 times.
Label source:
PubMed: Pharmacology research & perspectives (2022)
Action type:
informational_none
Target id:
/intervention/pterostilbene
Target name:
Pterostilbene
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Similar to resveratrol, pterostilbene may activate sirtuin enzymes that require NAD+ (provided by NMN) to function, potentially leading to a synergistic effect.
Actionable advice:
Consider taking pterostilbene at the same time as NMN to potentially enhance sirtuin activity.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: pterostilbene (like resveratrol) is a proposed sirtuin activator; pairing it with the NAD+ substrate from NMN could complement sirtuin signalling. Plausible, unstudied combination.
Label source:
Class inference
Action type:
informational_none
Target id:
/intervention/quercetin
Target name:
Quercetin
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin may both activate sirtuin enzymes and inhibit the CD38 enzyme that degrades NAD+, potentially creating a dual synergistic effect when combined with NMN.
Actionable advice:
Consider taking quercetin with NMN to potentially enhance sirtuin activity and preserve NAD+ levels.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
In this study, we established a novel approach to effectively utilize NAD+ for skin anti-aging by enhancing the pharmacological efficacy of exogenous NAD+ using a phytochemical complex consisting of quercetin, and enoxolone through inhibition of CD38.
Label source:
PubMed: Novel Approach to Skin Anti-Aging: Boosting Pharmacological Effects of Exogenous Nicotinamide Adenine Dinucleotide (NAD+) by Synergistic Inhibition of CD38 Expression. (PMID 39513906)
Action type:
informational_none
Target id:
/intervention/apigenin
Target name:
Apigenin
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Apigenin may inhibit the CD38 enzyme, which breaks down NAD+. Combining it with NMN (an NAD+ precursor) may lead to a greater increase in NAD+ levels than either alone.
Actionable advice:
Consider taking apigenin with NMN to potentially protect the newly generated NAD+ from degradation.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: apigenin inhibits CD38, a major NAD+-consuming enzyme, so it could raise/preserve the NAD+ that NMN supplies. Coherent mechanism; the combination is not clinically studied.
Label source:
Class inference
Action type:
informational_none
Target id:
/intervention/niacin
Target name:
Niacin (High Dose)
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both NMN and high-dose niacin are NAD+ precursors. While they use different initial pathways, taking high doses of both could theoretically saturate the NAD+ synthesis machinery, though evidence is limited.
Actionable advice:
Caution may help when combining high-dose niacin with NMN; a healthcare provider is worth consulting.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
7.2 Bile Acid Sequestrants An in vitro study results suggest that the bile acid-binding resins have high niacin binding capacity.
Label source:
Action type:
informational_none
Target id:
/biomarker/complete-blood-count
Target name:
Complete Blood Count
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
While not consistently shown in human trials, NAD+ modulation can influence hematopoietic stem cells, and monitoring blood counts is a prudent, precautionary measure.
Actionable advice:
Consider monitoring your complete blood count (CBC) annually while taking NMN.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
monitor
Target id:
/dietary/hot-foods-beverages
Target name:
Hot Foods or Beverages
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Liposomal NMN relies on a heat-sensitive phospholipid bilayer to protect and deliver its payload. Stirring it into a hot beverage (coffee, tea, soup) can melt or rupture the liposomes, destroying the enhanced-absorption advantage that is the entire point of the liposomal form.
Actionable advice:
Liposomal NMN should not be added to hot drinks or food. It should be taken with cool or room-temperature liquid to keep the liposomes intact.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Mechanism / liposome thermal stability
Exact phrase from label:
Phospholipid liposomal delivery systems are thermally labile and lose bilayer integrity when exposed to hot liquids, negating the absorption advantage of the liposomal format.
Label source:
Mechanistic inference
Action type:
avoid
Derived From
nmn_systemic_healthspan
Provenance Note
Interactions duplicated from 'nmn_systemic_healthspan'. Liposomal NMN; same interactions.